Table 1.
Baseline characteristics of control subjects and patients with coronary heart disease.
| Characteristics | Control (n = 1082) | CAD (n = 950) | p value |
|---|---|---|---|
| Age | 56.67 ± 8.73 | 58.68 ± 7.29 | 0.981 |
| Male gender, n (%) | 514 (46.43) | 436 (47.14) | 0.746 |
| Smoking, n (%) | 327 (30.31) | 453 (47.62) | < 0.001* |
| BMI, kg/m2 | 25.56 ± 4.02 | 26.37 ± 3.46 | < 0.001* |
| SBP, mmHg | 134.99 ± 22.61 | 150.50 ± 31.83 | < 0.001* |
| DBP, mmHg | 85.42 ± 16.63 | 92.10 ± 20.46 | < 0.001* |
| Hypertension, n (%) | 485 (45.07) | 516 (54.3) | < 0.001* |
| Uric Acid, mmol/L | 270.74 ± 85.22 | 310.77 ± 112.61 | < 0.001* |
| Glucose, mmol/L | 5.30 ± 1.90 | 6.23 ± 2.62 | < 0.001* |
| Diabetes, n (%) | 88 (8.13) | 233 (24.53) | < 0.001* |
| TG, mmol/L | 1.56 ± 1.07 | 2.03 ± 1.33 | < 0.001* |
| TC, mmol/L | 4.27 ± 0.93 | 4.38 ± 1.63 | 0.058 |
| HDL-C, mmol/L | 1.25 ± 0.47 | 0.98 ± 0.40 | < 0.001* |
| LDL-C, mmol/L | 2.66 ± 0.69 | 2.68 ± 0.98 | 0.591 |
| Statin therapy, n (%) | 124 (11.46) | 238 (25.05) | < 0.001* |
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG triglyceride, LDL-Clow density lipoprotein-cholesterol, HDL-C high density lipoprotein-cholesterol.
*Compared with control group, p-values < 0.001.